Biopharma Daily Updates - 12/18/20

$XBI $147.55 (+0.61%) 📈

PIPELINE:

$KPTI (+8.4%) - Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

https://investors.karyopharm.com/2020-12-18-Karyopharm-Announces-FDA-Approval-of-XPOVIO-R-Selinexor-as-a-Treatment-for-Patients-with-Multiple-Myeloma-After-At-Least-One-Prior-Therapy

$MESO (-31.7%) - Mesoblast Update on COVID-19 ARDS Trial

http://investorsmedia.mesoblast.com/static-files/bc0ce366-1c50-46ce-a9d4-d06b7ce403e5

$MRNA (-2.62%) - Moderna Announces FDA Authorization of Moderna COVID-19 Vaccine in U.S.

https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-fda-authorization-moderna-covid-19-vaccine-us

$OYST (-5.5%) - Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

https://investors.oysterpointrx.com/news-releases/news-release-details/oyster-point-pharma-submits-new-drug-application-us-food-and